Ocugen’s OCU410 shows early Phase 2 promise as a modifier gene therapy for geographic atrophy in dry AMD
Find out how Ocugen’s early Phase 2 results for OCU410 are shaping a new gene therapy approach for geographic atrophy in dry AMD.
Is bilateral delivery becoming the new standard in retinal gene therapy?
GenSight Biologics S.A.’s GS010/LUMEVOQ rollout in France and Israel has done more than expand access—it may be redefining how gene therapies are delivered in ophthalmology. As the company prepares for bilateral administration under early access programs for Leber Hereditary Optic Neuropathy (LHON), it is stepping into a growing shift across the field: a move away […]